ZA201906004B - Anti-par2 antibodies and uses thereof - Google Patents
Anti-par2 antibodies and uses thereofInfo
- Publication number
- ZA201906004B ZA201906004B ZA2019/06004A ZA201906004A ZA201906004B ZA 201906004 B ZA201906004 B ZA 201906004B ZA 2019/06004 A ZA2019/06004 A ZA 2019/06004A ZA 201906004 A ZA201906004 A ZA 201906004A ZA 201906004 B ZA201906004 B ZA 201906004B
- Authority
- ZA
- South Africa
- Prior art keywords
- par2
- antibodies
- antigen
- binding fragments
- par2 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472462P | 2017-03-16 | 2017-03-16 | |
| US201862637766P | 2018-03-02 | 2018-03-02 | |
| PCT/EP2018/056776 WO2018167322A1 (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201906004B true ZA201906004B (en) | 2025-10-29 |
Family
ID=61827709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/06004A ZA201906004B (en) | 2017-03-16 | 2019-09-11 | Anti-par2 antibodies and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10836822B2 (enExample) |
| EP (1) | EP3596125B1 (enExample) |
| JP (3) | JP7222901B2 (enExample) |
| KR (1) | KR102711884B1 (enExample) |
| CN (1) | CN110446720B (enExample) |
| AU (3) | AU2018235031B2 (enExample) |
| BR (1) | BR112019018752A2 (enExample) |
| CA (1) | CA3055251A1 (enExample) |
| CL (1) | CL2019002626A1 (enExample) |
| CO (1) | CO2019010975A2 (enExample) |
| CR (1) | CR20190417A (enExample) |
| IL (1) | IL269134B2 (enExample) |
| MA (1) | MA49886A (enExample) |
| MX (1) | MX2019010802A (enExample) |
| NZ (1) | NZ757915A (enExample) |
| PH (1) | PH12019502087A1 (enExample) |
| PT (1) | PT3596125T (enExample) |
| SG (1) | SG11201908056QA (enExample) |
| TW (1) | TWI788332B (enExample) |
| UA (1) | UA125757C2 (enExample) |
| WO (1) | WO2018167322A1 (enExample) |
| ZA (1) | ZA201906004B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| CN112812184A (zh) | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TWI617580B (zh) | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| KR102650420B1 (ko) | 2014-12-19 | 2024-03-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| TW202300168A (zh) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
| CN110446720B (zh) * | 2017-03-16 | 2023-09-12 | 免疫医疗有限公司 | 抗par2抗体及其用途 |
| US12214216B1 (en) | 2019-10-16 | 2025-02-04 | Helen Feng | Photon enhanced bone growth system and method |
| US11725052B2 (en) | 2020-08-18 | 2023-08-15 | Cephalon Llc | Anti-PAR-2 antibodies and methods of use thereof |
| GB202204159D0 (en) | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| AU2024212070A1 (en) | 2023-01-25 | 2025-07-31 | Medimmune Limited | Migraine therapy |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
| WO2025191185A1 (en) | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| EP1604207A2 (en) * | 2003-03-11 | 2005-12-14 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| JP2008519039A (ja) * | 2004-11-04 | 2008-06-05 | ニュー イングランド メデカル センター ホスピタルズ インク | Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法 |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CA2722600C (en) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| JP2011530515A (ja) | 2008-08-05 | 2011-12-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐａｒ−２活性化のエフェクターおよび炎症の調節におけるその使用 |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| WO2011111007A2 (en) | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| WO2014028354A1 (en) * | 2012-08-13 | 2014-02-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| US10183994B2 (en) * | 2014-06-30 | 2019-01-22 | Merck Patent Gmbh | Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence |
| CN110446720B (zh) * | 2017-03-16 | 2023-09-12 | 免疫医疗有限公司 | 抗par2抗体及其用途 |
-
2018
- 2018-03-16 CN CN201880018128.7A patent/CN110446720B/zh active Active
- 2018-03-16 IL IL269134A patent/IL269134B2/en unknown
- 2018-03-16 EP EP18714185.8A patent/EP3596125B1/en active Active
- 2018-03-16 MA MA049886A patent/MA49886A/fr unknown
- 2018-03-16 NZ NZ757915A patent/NZ757915A/en unknown
- 2018-03-16 CA CA3055251A patent/CA3055251A1/en active Pending
- 2018-03-16 PT PT187141858T patent/PT3596125T/pt unknown
- 2018-03-16 US US15/923,374 patent/US10836822B2/en active Active
- 2018-03-16 BR BR112019018752-9A patent/BR112019018752A2/pt unknown
- 2018-03-16 KR KR1020197030092A patent/KR102711884B1/ko active Active
- 2018-03-16 TW TW107109179A patent/TWI788332B/zh active
- 2018-03-16 AU AU2018235031A patent/AU2018235031B2/en active Active
- 2018-03-16 CR CR20190417A patent/CR20190417A/es unknown
- 2018-03-16 UA UAA201910275A patent/UA125757C2/uk unknown
- 2018-03-16 WO PCT/EP2018/056776 patent/WO2018167322A1/en not_active Ceased
- 2018-03-16 JP JP2019549512A patent/JP7222901B2/ja active Active
- 2018-03-16 SG SG11201908056QA patent/SG11201908056QA/en unknown
- 2018-03-16 MX MX2019010802A patent/MX2019010802A/es unknown
-
2019
- 2019-09-11 ZA ZA2019/06004A patent/ZA201906004B/en unknown
- 2019-09-13 CL CL2019002626A patent/CL2019002626A1/es unknown
- 2019-09-13 PH PH12019502087A patent/PH12019502087A1/en unknown
- 2019-10-03 CO CONC2019/0010975A patent/CO2019010975A2/es unknown
-
2020
- 2020-09-29 US US17/035,956 patent/US11591389B2/en active Active
-
2021
- 2021-10-27 AU AU2021257983A patent/AU2021257983B2/en active Active
-
2023
- 2023-02-03 JP JP2023015469A patent/JP2023055895A/ja active Pending
- 2023-02-07 US US18/165,614 patent/US20230242639A1/en not_active Abandoned
-
2025
- 2025-03-18 JP JP2025043151A patent/JP2025102812A/ja active Pending
- 2025-05-27 AU AU2025203947A patent/AU2025203947A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502087A1 (en) | Anti-par2 antibodies and uses thereof | |
| MX2024000742A (es) | Anticuerpos anti-tigit. | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| PH12020551997A1 (en) | Psma binding agents and uses thereof | |
| PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| MX2022012749A (es) | Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas. | |
| PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| PH12017502180A1 (en) | Tau-binding antibodies | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| PH12019500552A1 (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
| MY198562A (en) | Antibodies specifically binding pd-1 and their uses | |
| MX2018003689A (es) | Proteinas de union a pd-1 y metodos para usarlas. | |
| AU2016320748A8 (en) | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies | |
| EP3176181A4 (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| MY193677A (en) | Tau-binding antibodies | |
| PH12019500551A1 (en) | Antibody specifically binding to il-17a and functional fragment thereof | |
| AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| NZ759835A (en) | Cd38 modulating antibody | |
| WO2018227063A8 (en) | Anti-robo2 antibodies, compositions, methods and uses thereof | |
| MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
| WO2021041300A3 (en) | Bispecific antibodies and uses thereof | |
| WO2020003172A8 (en) | Transthyretin antibodies and uses thereof |